Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bumetanide oral - Neurochlore

Drug Profile

Bumetanide oral - Neurochlore

Alternative Names: Bumetanide oral liquid - Neurochlore; S 95008

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurochlore
  • Developer ADIR; Neurochlore; Servier
  • Class Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Benzoic acids; Heart failure therapies; Sulfonamides
  • Mechanism of Action Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pervasive child development disorders

Most Recent Events

  • 07 Sep 2021 Servier and Neurochlore terminates phase III trial in Pervasive child development disorders in Brazil, Czech Republic, Slovakia, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain and the United Kingdom, due to low efficacy (NCT03715166)
  • 07 Sep 2021 Servier and Neurochlore terminates phase III trial in Pervasive child development disorders in USA, Australia, Czech Republic, Slovakia, Brazil, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain and the United Kingdom due to low efficacy (NCT03715153)
  • 04 Oct 2018 Phase-III clinical trials in Pervasive child development disorders (In children) in Australia, USA (PO) (NCT03715153)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top